1. Dosage of Atg5 Gene Affects Pancreatic Tumorigenesis and Progression
Haiyong Han 
Gastroenterology 
Volume 156, Issue 1, Pages (January 2019)
DOI: /j.gastro
Copyright © 2019 AGA Institute Terms and Conditions

2. Figure 1
Atg5 gene dosage affects pancreatic tumor initiation, progression, and metastasis in mice. In mice harboring oncogenic Kras, biallelic deletion of Atg5 (Atg5-/-; bottom row) enhances acinar-to-ductal metaplasia (ADM) compared with mice with wild-type Atg5 (Atg5+/+; top row), indicating accelerated tumor initiation. However, the ADM lesions in Atg5-/- mice only progress to the pancreatic intraepithelial neoplasia (PanIN)-1 stage, and the Atg5-/- mice have reduced survival owing to severe pancreatic degeneration. In contrast, mice with monoallelic deletion of Atg5 (Atg5+/-; middle row) exhibit a level of ADM induction and progression to PanIN similar to that of Atg5+/+ mice. However, the Atg5+/- mice have a higher incidence of malignant pancreatic ductal adenocarcinoma (PDAC) and metastasis than the Atg5+/+ mice, suggesting that monoallelic loss of Atg5 can drive pancreatic tumor progression and metastasis in the presence of oncogenic Kras.
Gastroenterology  , 17-19DOI: ( /j.gastro )
Copyright © 2019 AGA Institute Terms and Conditions